This post is also available in: Japanese
Asahi Kasei has made a cash offer to acquire Sweden’s Calliditas Therapeutics in a deal worth 11.16 billion Swedish crowns ($1.06 billion). Calliditas has full FDA approval for its primary immunoglobulin A nephropathy (IgAN) treatment Tarpeyo and is listed on Nasdaq in New York and Stockholm.
Asahi Kasei already owns several companies in Europe, employing around 650 people, stemming from various acquisitions made since 2012, but is mainly known for chemicals related building materials such as insulation, coating and rubber. It states that this acquisition is to establish a presence in Europe (presumably in pharmaceuticals), initially focused on R&D; and to expand the scope of its in-licensing and new drug development opportunities.
Calliditas has around 200 employees with offices in Sweden, France, US and Switzerland.
For more content like this, subscribe to the free Rudlin Consulting Newsletter. 最新の在欧日系企業の状況については無料の月刊Rudlin Consulting ニューズレターにご登録ください。
